the contribution of Rho-kinase in CRC development in patients. Our data showed that the ROCK1 and ROCK2 genes might be a risk factor for CRC development and that genetic polymorphisms in these genes may modify individual susceptibility to CRC in the Turkish population.
gratory phenotype are initial steps of epithelial cancer, and most invasive colorectal carcinomas develop from intraepithelial neoplasms (adenomas). Accumulating evidence indicates that the Rho/Rho-kinase pathway plays an important role in various cellular functions, such as vascular smooth muscle cell contraction, cell migration, proliferation and actin cytoskeletal rearrangement, including stress fiber formation and tumor invasion [4] [5] [6] . It has been suggested that the Rho/Rho-kinase pathway is involved in several proinvasive pathways, including src and Wnt [7] [8] . However, the exact role that Rho-kinase plays in cancer cells remains to be elucidated.
It has now been well established that CRC arises as a consequence of the progressive accumulation of genetic and epigenetic changes that leads to the conversion of normal colonic epithelial cells to dysplasia, followed by adenomas and adenocarcinomas [9, 10] . Activating ROCK1 mutations that increase cellular motility through actin cytoskeleton rearrangement have been identified in breast and lung carcinomas [11] . We have previously shown that there is a significant association between the ROCK2 gene polymorphism and risk of developing metastases of breast cancer [12] . The purpose of the present study was to investigate a possible association between Rho-kinase polymorphisms and CRC in a Turkish population. Involvement of the Rho-kinase protein expressions in CRC has also been evaluated.
Materials and Methods

Study Populations
This retrospective study used data from 85 patients (36 female and 49 male, aged 11-91 years, mean 61.9 8 16.1 years) who underwent surgery for colorectal cancer between 2003 and 2010 at the Gaziantep University Hospital. Patients were identified from the surgical and pathological records and all cases were confirmed by histological evaluation. Specimens from patients who had undergone surgery for colonic cancer were obtained from the pathology department. For the immunohistochemical studies, controls were from the nonneoplastic tissue sections adjacent to the tumors of the studied patients. For the polymorphism studies, 178 unrelated healthy volunteers (89 female and 89 male, aged 25-88 years, mean 57.9 8 17.0) were included in the study and constituted the control group. Volunteers in this control group had no personal or familial history of CRC, colorectal polyps or other lesions in the colon. Patients and controls were of the same ethnic origin and from the same geographical area (southeastern Turkey). The study was approved by the local ethics committee and written informed consent was obtained from healthy volunteers before entering the study. The eligibility criteria for patients included: histologically confirmed CRC (adenocarcinomas); indication for first-line treatment with chemotherapy, and not having received preoperative radiotherapy. Tumor staging was recorded according to the tumor-node-metastasis staging system. The characteristics of cancer cases and the effects of confounding factors are given in table 1 .
Blood Samples and DNA Isolation
For the control group, 5-ml samples of peripheral blood from healthy volunteers were collected by venipuncture into sterile siliconized Vacutainer tubes with 2 mg/ml disodium ethylenediaminetetraacetic acid. All samples were stored at -20 ° C until use. Genomic DNA was extracted from whole blood using the saltingout method and stored at -20 ° C [13] . For the patient group, DNA was isolated from paraffin-embedded blocks by using DNA isolation kit (Qiamp DNA FPPE Tissue Kit, Qiagen, Valencia, Calif., USA). 
Genotyping
The Fluidigm Digital Array is a nanofluidic biochip where digital PCR reactions can be performed with isolated individual DNA template molecules. Polymorphisms were analyzed in genomic DNA using a 96.96 dynamic array on the BioMark HD system (Fluidigm, South San Francisco, Calif., USA). The Digital PCR Analysis software (Fluidigm) was used to process the data after the reaction. Chambers that yielded signals were detected and counted. In the present study, 2 single nucleotide polymorphisms (rs73963110 and rs35996865) were studied for ROCK1 gene polymorphisms, and 9 polymorphisms (rs2230774, rs35768389, rs34945852, rs1515219, rs2290156, rs965665, rs10178332, rs6755196 and rs10929732) were examined for ROCK2 gene polymorphisms.
Immunohistochemistry
Formalin-fixed, paraffin wax-embedded blocks from each case were selected for immunohistochemical studies using the antibodies against p53 and ROCK. Control tissue sections were from the nonneoplastic colon tissue adjacent to the tumors from the studied patients. Four-micrometer sections were cut from paraffin-embedded tissue blocks onto silane-coated slides. Sections were heated to 60 ° C for 20 min prior to the deparaffinization with xylene solution. Sections were then stained by using the Ventana Ultraview DAB detection kit in a Ventana BenchMark XT automated slide processing system (Ventana Medical Systems Inc., Tucson, Ariz., USA). Rabbit monoclonal ROCK1 antibody (1: 100; Abcam, Cambridge, UK), rabbit polyclonal ROCK2 antibody (1: 100; Abcam) and mouse monoclonal p53 antibody (1: 100; Cell Marque, Rocklin, Calif., USA) were used for ROCK1, ROCK2 and p53 immunostaining, respectively. The percentage of cell staining and intensity (-, +, ++, or +++) was evaluated and scored from 1 to 4.
Statistical Analyses
Results are expressed as mean 8 standard deviation (SD). Statistical analysis was performed using GraphPad Instat version 3.05 (GraphPad Software Inc., San Diego, Calif., USA). The 2 test was used for calculation of the significance of differences in ge notype and allele frequencies. For comparisons of the differences between mean values of 2 groups, unpaired Student's t test was used. Pearson's test was used to identify the correlations. The MannWhitney U-test was used to detect significant differences between immunohistochemical scores. All statistical tests and p values were two-sided, and p ! 0.05 was considered statistically significant.
Results
Distributions of genotypes and alleles between the CRC patients and control groups are shown in table 2 .
ROCK1 Gene Polymorphisms
Both rs73963110 and rs35996865 polymorphisms of the ROCK1 gene were significantly associated with CRC development. CT genotype (89.3 vs. 7.7%, p ! 0.0001) and T allele (50.0 vs. 9.0%, p ! 0.0001) frequencies of the rs73963110 polymorphism were significantly higher in CRC patients compared to controls. However, TT 
ROCK2 Gene Polymorphisms
Although there were significant associations between ROCK2 gene rs2290156, rs10178332, rs35768389 (Asp601Val), rs10929732 and rs34945852 (Lys1083Met) polymorphisms with CRC development, no marked associations were found between ROCK2 gene rs965665, rs2230774 (Thr431Asn), rs6755196 and rs1515219 polymorphisms ( table 2 ) . Although homozygous carriers of the GG (11.5 vs. 60.6%) and CC (10.3 vs. 29.9%) genotypes of the rs2290156 polymorphism were less frequent, heterozygous carriers of the GC genotype (78.2 vs. 9.5%) were more frequent among the metastatic patients than among the controls (p ! 0.0001). C allele was also more frequent amongst the CRC patients (49.4 vs. 34 Immunohistochemical Staining ROCK1 and ROCK2 immunohistochemical staining were markedly elevated in the tumor tissue ( fig. 1 ) . A widespread stronger positivity for ROCK1 and ROCK2 staining was observed in the cytoplasm of the colon cells from CRC patients. The ROCK distribution displayed a similar pattern between control and CRC sections. There was a marked increase in ROCK1 immunohistochemical staining scores in tumor tissue (3.36 8 0.76, n = 81, p ! 0.0001) when compared to healthy control tissue (1.56 8 0.50, n = 81). Similarly, ROCK2 immunohistochemical staining scores were also significantly augmented in tumor tissue (3.56 8 0.61, n = 81, p ! 0.0001) when compared to healthy controls (1.61 8 0.49, n = 81). Positive nuclear staining of p53 was markedly high in tumor tissue (2.06 8 0.78, n = 81), while it was absent in normal colon cells ( fig. 2 ) .
Correlations
Significant correlations between the prognostic factors and Rho-kinase in CRC patients are shown in table 3 . Vascular (small vessels and mural) and perineural invasion were observed in 11 and 7 patients, respectively. It has been found that there were significant negative correlations between vascular and perineural invasions with ROCK2 protein expressions. However, positive correlations were found between vascular and perineural invasions with p53 expression. We noted a negative correlation between lymph node involvement and tumor differentiation in CRC patients ( table 3 ) .
Discussion
These results are the first to demonstrate the contribution of Rho-kinase in CRC development in patients. Our data have shown that the ROCK1 and ROCK2 genes might be a risk factor for CRC, and may modify individual susceptibility to CRC in the Turkish population. Rho-kinases are likely to exist as dimers by parallel association at the coiled-coil domain, and the dimerized kinase domain of Rho-kinase appears to be in an active conformation in the absence of phosphorylation [14] . Since the dimeric structure is essential for normal in vivo function [15] , mutational changes in the structure could be hypothesized to effect dimerization and Rho binding, and thereby ROCK activation and phosphorylation of its substrates.
The majority of cancer deaths result from tumor metastases rather than from primary tumors. However, the biochemical mechanisms that regulate invasion and metastasis remain incompletely defined. Colon carcinoma invasiveness is a process involving cell-cell and cell-matrix alterations, local proteolysis of the extracellular matrix or changes in cytokine and growth factor levels. Increased ROCK signaling is sufficient to promote invasion from solid tumors and ROCK contributes to tumor angiogenesis [16] . Increased ROCK signaling resulted in changes to epithelial morphology and organization that facilitated motility in vitro, most likely by inducing the redistribution of proteins such as ezrin, as well as adherens junction and extracellular matrix-binding proteins. Rho GTPases and Rho-kinase are required for the activa- tion of the actin cytoskeleton and epithelial cell movements and invasiveness [6] . It has been suggested that ROCK inhibitors would be useful antimetastatic and antiangiogenic agents in tumors associated with elevated RhoA, RhoC, ROCK1 or ROCK2 expression [16] . Rhokinase has been linked with greater invasion in several solid tumors [17, 18] . Furthermore, elevated RhoA/Rhokinase activity promotes cancer cell invasion and eventually leads to metastasis by disrupting E-cadherin-mediated adherens junctions and degradation of the extracellular matrix [19] . There is evidence that ROCK inhibition reduces the invasiveness of several tumor cell lines [20] [21] [22] . In the highly tumorigenic intestinal epithelial cell lines, ROCK2 knockdown with ROCK2 siRNA resulted in a two-fold or more reduction in invasion [23] . Src activation is an early and frequent event in human colon cancers. It has been found that cellular invasion induced by the src oncogene is abrogated by inhibitors of the RhoA/ ROCK pathway [24] . Platelet-derived endothelial cell growth factor (PD-ECGF) expression may be associated with colon cancer cell migration via activation of ROCK1. This may explain one mechanism by which tumors with high expression of PD-ECGF show aggressive behavior [25] . The specific Rho-kinase inhibitor Y-27632 also decreased metalloproteinases-2 secretion by human colon adenocarcinoma cell lines [26] . Taken together, these re- sults indicate that the Rho/Rho-kinase pathway plays a role in colon cancer cell migration and invasion. These findings also imply that the Rho/Rho-kinase pathway may become a molecular target for the prevention of cancer invasion and metastasis. There are also contradicting results related to the role of the Rho/Rho-kinase pathway in cancer. A recent study showed that the activation of Rho-kinase leads to an inhibition of motility in human breast cancer cells [27] . The active vitamin D metabolite 1,25-dihydroxyvitamin D3, used as an anticancer agent, inhibits the proliferation and promotes the differentiation to a normal adhesive epithelial phenotype of human colon cancer cells via augmentation of cytosolic Ca 2+ concentration and activation of RhoA/Rho-kinase [28] . The inactivation of the Rho/Rhokinase pathway has been shown to promote oncogenic Ras-induced transformation in fibroblast cells [29] , thus suggesting Rho-kinase to play a negative role in oncogenic cells. There are also reports showing that the inhibition of Rho-kinase stimulates colon cancer cell proliferation, progression and migration [30, 31] . Cell motility and migration were found to be significantly increased with Y-27632 in human colorectal cancer cells [30, 32] . This negative role for Rho-kinase in colon cancer cell migration may be mediated by altering focal adhesion formation via the Akt pathway [32] . Therefore, the precise mechanism of Rho-kinase in carcinogenesis and the progression of human cancers have not been fully elucidated. Additionally, the contribution of the Rho/Rho-kinase pathway to colorectal cancer progression and invasion remains controversial.
ROCK1 and ROCK2 immunohistochemical staining were markedly elevated in the tumor tissue suggesting that there was a marked increase in Rho-kinase protein expression in CRC patients. This study is the first to demonstrate that ROCK1 and ROCK2 protein expressions are markedly augmented in CRC patients.
The tumor suppressor protein p53 plays a pivotal role in the maintenance and regulation of normal cellular functions [33] . p53 is activated in response to various cellular stress signals, forming a transcription factor able to modulate the expression of numerous downstream genes including cell cycle regulation, apoptosis, cellular signaling, angiogenesis and regulation of the extracellular matrix [34] [35] [36] . Additionally, p53 interacts with a number of proteins and has also recently been implicated in the regulation of angiogenic transcription factors and vascular development, which are important features of metastasis [37] . The TP53 gene has important functions in DNA damage repair and apoptosis [38] . Mutations in the TP53 gene are observed in approximately 50% of human CRC [33, 39] and increased expression of mutant forms of p53 oncogene protein was found in colorectal adenocarcinoma [40] . p53 mutational inactivation is frequently associated with the transition from benign adenomas to malignant carcinomas [41] . Although the transcription factor p53 regulates the expression of several Rho pathway signaling molecules, modulation of Rho pathway signaling by p53 appears to be cell dependent [42] . Recently, it has been shown that ROCK inhibits the p53-mediated apoptosis pathway in hepatocellular carcinoma cells [43] . However, the molecular links between Rho/ROCK pathway and p53 expression in CRC metastatic progression are still unknown.
In conclusion, the findings of the present study show that the ROCK1 and ROCK2 genes might be a risk factor for CRC and suggest that genetic polymorphisms in the ROCK gene modify individual susceptibility to CRC in the Turkish population. Our findings also imply that genotyping ROCK1 and ROCK2 gene polymorphisms may help in predicting the prognosis of CRC and can be used as a marker for early diagnosis. As genetic polymorphisms often vary among ethnic groups, further studies are required to verify the association of the ROCK polymorphisms with the risk of CRC in diverse ethnic populations and in independent cohorts. Immunohistochemical staining or determination of Rho-kinase in patients with CRC may be helpful in medical management and risk stratification, and may provide important insight into the future development of potential therapeutic approaches for CRC patients.
